KL-A167
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for KL-A167, covering 2023-10-23 to 2026-01-27. Get the full timeline:
Most recent: Clinical Trial Update: Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer [Phase 2]